CMMB News and Press, Chemomab Therapeutics Ltd. From 02/20/24

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases PR Newswire —CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topl...

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnolo...

Chemomab Therapeutics to Participate in Upcoming Investor Conferences PR Newswire TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development...

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis PR Newswire —Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-rela...

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 PR Newswire —Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient ...

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis PR Newswire --Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Dis...

2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...

2023-11-15 07:55:27 ET More on Chemomab Therapeutics Chemomab Therapeutics receives Nasdaq notice regarding minimum bid price requirement Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial...

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis PR Newswire —CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Conditionȁ...

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 PR Newswire — ...